• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

    6/17/25 4:05:00 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRDF alert in real time by email

    – Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development –

    – Company will hold a conference call on July 29 at 4:30 p.m. ET/1:30 p.m. PT to share additional clinical data from its randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") –

    SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the company has appointed Roger Sidhu, MD, as Chief Medical Officer. Dr. Sidhu is a veteran executive and clinician with over 20 years of experience and a strong track record of success in oncology research, development, and regulatory strategy. Dr. Sidhu succeeds Dr. Fairooz Kabbinavar who will remain with the company in an advisory role. The company also announced it will share additional clinical data from its lead program in RAS-mutated mCRC on July 29, 2025.

    "We are pleased to welcome Dr. Sidhu to lead the clinical program for onvansertib through the next phase of development. Dr. Sidhu is a respected clinician and seasoned executive with a proven track record of advancing innovative therapies through late-stage clinical development across multiple therapeutic areas including in first-line mCRC. As we move forward, we thank Dr. Kabbinavar for his leadership in progressing onvansertib's clinical development across multiple tumor types," said Mark Erlander, Chief Executive Officer of Cardiff Oncology. "In addition to today's medical leadership transition, we are announcing our plan to share an update of clinical data from the ongoing CRDF-004 trial on July 29, at which point we expect to release a substantive dataset."

    "I am honored to join the executive team at Cardiff Oncology as we advance onvansertib through late-stage clinical development, and make a meaningful impact for patients living with cancer," said Roger Sidhu, MD. "With a strong foundation already in place, I'm stepping into this role at an exciting time as we prepare to share a clinical update on our lead program in RAS-mutated mCRC next month."

    Dr. Sidhu was most recently the Chief Medical Officer and acting CEO at Treadwell Therapeutics. Previously, Dr. Sidhu spent nearly 10 years at Amgen in roles of increasing responsibility in the Hematology/Oncology therapeutic area where he advanced multiple therapeutic candidates. In mCRC, he led multiple phase 3 clinical trials of panitumumab (Vectibix®) in monotherapy and in combination with chemotherapy leading to approvals in the U.S. and globally. Dr. Sidhu was also a leader in advancing the science of RAS biology and therapeutics in mCRC and has published work in several peer reviewed journals including the New England Journal of Medicine.

    In addition, Dr. Sidhu served as Executive Vice President and Chief Medical officer at Roivant Sciences. He was also the Chief Medical Officer at Eterna Therapeutics, Inc. and Cell Design Labs, up until its acquisition by the Gilead subsidiary Kite, where he subsequently served as VP, Clinical Development.

    Dr. Sidhu is a Fellow of the Royal College of Physicians and Surgeons of Canada in both internal medicine and medical oncology. He earned his medical degree from Queen's University in Kingston, Ontario Canada and his bachelor's degree in biochemistry from the University of Alberta in Edmonton, Alberta. Dr. Sidhu trained in internal medicine at Queen's University and medical oncology at the British Columbia Cancer Agency in Vancouver, British Columbia and the Cross Cancer Institute in Edmonton, Alberta.

    Conference Call and Webcast on Additional Clinical Data from CRDF-004 in mCRC

    Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on July 29, 2025 to share additional clinical data from the CRDF-004 trial in first-line RAS-mutated mCRC. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors.cardiffoncology.com/news-events/events. A replay will be available in the investor relations section on the company's website following the completion of the call.

    Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    In connection with Dr. Sidhu joining Cardiff Oncology, the Company's Board of Directors approved the grant of non-qualified stock options to purchase 600,000 shares of Cardiff Oncology common stock outside of the Cardiff Oncology 2021 Omnibus Equity Incentive Plan. The stock option was granted as an inducement material to Dr. Sidhu becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The option was granted as of June 16, 2025 and has an exercise price of $3.86 per share, the closing price on the grant date. The option vests over four years with 25% vesting after 12 months and the remaining shares vesting monthly over the following 36-months, subject to Dr. Sidhu's continued employment with Cardiff Oncology on such vesting dates.

    About Cardiff Oncology, Inc.

    Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

    Forward-Looking Statements

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate; results of preclinical studies or clinical trials for our product candidate could be unfavorable or delayed; our need for additional financing; risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber-attacks on our information technology infrastructure, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that our product candidate will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

    Cardiff Oncology Contact: 

    James Levine

    Chief Financial Officer

    858-952-7670

    [email protected]

    Investor Contact:

    Kiki Patel, PharmD

    Gilmartin Group

    332-895-3225

    [email protected]

    Media Contact:

    Meghan Bianco

    Taft Communications, a division of RF|Binder

    609-544-5446

    [email protected]



    Primary Logo

    Get the next $CRDF alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CRDF

    DatePrice TargetRatingAnalyst
    6/24/2025$3.50Hold
    Jefferies
    9/6/2024$8.00Buy
    Craig Hallum
    2/28/2022$26.00 → $25.00Buy
    HC Wainwright & Co.
    1/5/2022Outperform
    William Blair
    12/8/2021$19.00Outperform
    Robert W. Baird
    12/8/2021$19.00Outperform
    Baird
    8/10/2021$25.00 → $26.00Buy
    HC Wainwright & Co.
    8/9/2021$30.00 → $20.00Buy
    Maxim Group
    More analyst ratings

    $CRDF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Tannenbaum Renee P

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      6/30/25 9:39:52 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Markin Rodney S

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      6/30/25 9:38:55 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Mohindru Mani

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      6/30/25 9:38:05 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    SEC Filings

    See more
    • Cardiff Oncology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Cardiff Oncology, Inc. (0001213037) (Filer)

      6/26/25 4:30:47 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Cardiff Oncology, Inc. (0001213037) (Filer)

      6/17/25 4:15:28 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Cardiff Oncology Inc.

      EFFECT - Cardiff Oncology, Inc. (0001213037) (Filer)

      5/14/25 12:15:22 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

      – Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – – Company will hold a conference call on July 29 at 4:30 p.m. ET/1:30 p.m. PT to share additional clinical data from its randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") – SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announc

      6/17/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

      – Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of onvansertib in combination with paclitaxel, and objective responses were observed only at the highest dose of onvansertib – – The combination was well-tolerated and demonstrated a safe and manageable toxicity profile – SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced positive data from an investigator-initiated Phase 1b cli

      6/2/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

      - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") - - Expanded intellectual property portfolio with second patent covering treatment of all bev-naïve patients, including RAS-mutated and RAS wild-type mCRC, across all lines of therapy - - Cash and investments of $79.9 million as of March 31, 2025, projected runway into Q1 2027 - SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial res

      5/8/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Cardiff Oncology with a new price target

      Jefferies initiated coverage of Cardiff Oncology with a rating of Hold and set a new price target of $3.50

      6/24/25 8:00:04 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Craig Hallum initiated coverage on Cardiff Oncology with a new price target

      Craig Hallum initiated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $8.00

      9/6/24 7:59:22 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Cardiff Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $25.00 from $26.00 previously

      2/28/22 7:10:55 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Levine James E. bought $36,726 worth of shares (7,716 units at $4.76) (SEC Form 4)

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      12/18/24 4:37:28 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Tannenbaum Renee P bought $34,224 worth of shares (10,000 units at $3.42), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      12/16/24 5:00:03 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Pace Gary W bought $940,199 worth of shares (361,615 units at $2.60), increasing direct ownership by 50% to 1,047,876 units (SEC Form 4)

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      12/12/24 4:05:04 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Financials

    Live finance-specific insights

    See more
    • Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

      – Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – – Company will hold a conference call on July 29 at 4:30 p.m. ET/1:30 p.m. PT to share additional clinical data from its randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") – SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announc

      6/17/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

      - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") - - Expanded intellectual property portfolio with second patent covering treatment of all bev-naïve patients, including RAS-mutated and RAS wild-type mCRC, across all lines of therapy - - Cash and investments of $79.9 million as of March 31, 2025, projected runway into Q1 2027 - SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial res

      5/8/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

      SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference call on Thursday, February 27 after the close of trading to review financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 27, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors

      2/20/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Leadership Updates

    Live Leadership Updates

    See more
    • Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update

      First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC) Introduced full membership of Scientific Advisory Board (SAB) Announced appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Cash, cash equivalents, and short-term investments of approximately $97 million as of March 31, 2023, projected runway into 2025 SAN DIEGO, May 4, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the first-q

      5/4/23 4:10:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer

      Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib  Served as the lead investigator for two practice-changing trials of bevacizumab (Avastin®) combinations leading to the approval of bevacizumab in metastatic colorectal cancer (mCRC)1,2 SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that it has strengthened its leadership team with the appointment of Fairooz Kabbinavar, MD, FACP, as

      2/2/23 8:00:00 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs

      SAN DIEGO, Jan. 11, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced the appointments of Tod Smeal, Ph.D., as chief scientific officer (CSO) and Charles Monahan, RPh, as senior vice president, regulatory affairs. "We are excited to welcome Tod and Charles to Cardiff Oncology as we approach key in

      1/11/22 8:00:00 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cardiff Oncology Inc. (Amendment)

      SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)

      2/6/24 4:01:34 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cardiff Oncology Inc. (Amendment)

      SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)

      2/14/23 12:47:09 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cardiff Oncology Inc.

      SC 13G - Cardiff Oncology, Inc. (0001213037) (Subject)

      1/26/23 1:30:22 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care